The US and European synthetic bone graft substitutes market is expected to grow at a compound annual growth rate of 4.53% during the forecast period of this report. Growth in this market will largely be driven by the widespread availability and adoption of 2nd generation synthetic bone graft substitutes that can demonstrate comparable (if not superior) clinical efficacy compared to autograft bone.
Growth will largely be driven an increased adoption of novel (osteostimulative) synthetic bone graft substitute products. This will be propelled by demonstrated clinical efficacy as well as additional product approvals in the US. The US represents the largest market accounting for approximately 79.2% of the synthetic bone graft substitutes market in 2021.
The European market accounted for approximately 20.8% in 2021. The Covid-19 pandemic significantly impacted the US and European market size/revenues in 2020 (a year-on-year decline of 9.87% in 2020) largely due to cancellations / postponement of elective procedures. Successful vaccine roll-outs, easing of restrictions and increased pressures on healthcare systems to reduce waiting lists, will allow both the US and European synthetic bone graft substitute markets to recover in 2022/2023 and grow during the forecast period.
US and European procedures numbers that utilize bone grafts (of any type) will increase from 1.82 million in 2021 to 2.35 million in 2027 (CAGR of 2.43% from 2019-2027) – growth will be driven by an increased prevalence of spinal fusion and trauma procedures that utilize bone grafts. The percentage of bone grafting procedures that utilize synthetic bone graft substitutes is forecast to increase from 24.55% in 2021 to 30.97% in 2027. Growth in this segment will be driven by reduced ASPs and increased adoption of novel (osteostimulative) synthetic bone graft substitutes that can demonstrate comparable clinical outcomes to autograft bone.